Stock Events

Stock Events

Mirum Pharmaceuticals 

$101.56
49
+$0.93+0.92% 15:04 Today

Statistics

Day High
101.79
Day Low
100.47
52W High
130
52W Low
63.23
Volume
1,077
Avg. Volume
-
Mkt Cap
6.19B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-13.43
-8.94
-4.44
0.05
Expected EPS
-0.525578
Actual EPS
N/A

Financials

-4.48%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
521.31MRevenue
-23.36MNet Income

Analyst Ratings

137.64Average Price Target
The highest estimate is 150.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
91%
Hold
9%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MIRM. It's not an investment recommendation.
NVIDIA
19
NVDA
Amazon
16
AMZN
Microsoft
15
MSFT
Apple
12
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in developing treatments for liver diseases, directly competing with Mirum's focus on rare liver conditions.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals works on RNAi therapeutics for a variety of conditions, including liver diseases, competing in the same therapeutic space as Mirum.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, positioning it as a competitor in the hepatology market.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has a diverse drug portfolio that includes treatments for liver diseases, making it a competitor in the same market as Mirum.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a wide range of pharmaceutical products, including treatments for liver conditions, competing with Mirum Pharmaceuticals.
Novartis
NVS
Mkt Cap292.35B
Novartis AG engages in the research, development, and marketing of healthcare products, including liver disease treatments, which puts it in competition with Mirum.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. offers a variety of healthcare products and services, including treatments for liver diseases, making it a competitor.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in multiple therapeutic areas, including liver diseases, directly competing with Mirum's product offerings.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a diverse portfolio in healthcare, including liver disease treatments, positioning it as a competitor to Mirum Pharmaceuticals.

About

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Show more...
CEO
Christopher Peetz
Employees
418
Country
United States
ISIN
US6047491013
WKN
000A2PM29

Listings

XETRA
DE
08D.XETRA
STU
DE
08D.STU
MX
MX
MIRM.MX
MU
DE
08D.MU

0 Comments

Share your thoughts

FAQ

What is Mirum Pharmaceuticals stock price today?▼
The current price of MIRM is $101.56 USD — it has increased by +0.92% in the past 24 hours. Watch Mirum Pharmaceuticals stock price performance more closely on the chart.
What is Mirum Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Mirum Pharmaceuticals stocks are traded under the ticker MIRM.
Is Mirum Pharmaceuticals stock price growing?▼
MIRM stock has risen by +4.52% compared to the previous week, the month change is a -2.36% fall, over the last year Mirum Pharmaceuticals has showed a +37.33% increase.
What is Mirum Pharmaceuticals market cap?▼
Today Mirum Pharmaceuticals has the market capitalization of 6.19B
When is the next Mirum Pharmaceuticals earnings date?▼
Mirum Pharmaceuticals is going to release the next earnings report on November 17, 2026.
What were Mirum Pharmaceuticals earnings last quarter?▼
MIRM earnings for the last quarter are -1.06 USD per share, whereas the estimation was -0.74 USD resulting in a -42.75% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Mirum Pharmaceuticals revenue for the last year?▼
Mirum Pharmaceuticals revenue for the last year amounts to 521.31M USD.
What is Mirum Pharmaceuticals net income for the last year?▼
MIRM net income for the last year is -23.36M USD.
How many employees does Mirum Pharmaceuticals have?▼
As of September 04, 2026, the company has 418 employees.
In which sector is Mirum Pharmaceuticals located?▼
Mirum Pharmaceuticals operates in the Health & Wellness sector.
When did Mirum Pharmaceuticals complete a stock split?▼
Mirum Pharmaceuticals has not had any recent stock splits.
Where is Mirum Pharmaceuticals headquartered?▼
Mirum Pharmaceuticals is headquartered in FOSTER CITY, United States.